AAV Drug Quality Control: Critical Quality Attributes and Analytical Challenges in Gene Therapy Manufacturing

With the rapid advancement of gene therapy, Adeno-Associated Virus (AAV) has emerged as a leading platform for in vivo gene delivery. As AAV-based therapeutics move from research into clinical and commercial stages, robust quality control frameworks have become essential. Central to these frameworks is the identification and measurement of critical quality attributes (CQAs)—properties that must be controlled to ensure product safety, efficacy, and consistency.

This article outlines the major CQAs for AAV products, the analytical challenges associated with their measurement, and current strategies to address these challenges.

Key Quality Attributes of AAV Products

AAV vectors are complex biological entities, and their quality cannot be defined by a single parameter. Instead, multiple CQAs must be evaluated in combination.

Purity
Purity reflects the proportion of AAV vector relative to process-related impurities, including host cell proteins, residual DNA, and empty capsids. High purity is essential to minimize immunogenicity and improve safety profiles.

Titer
Titer defines the concentration of AAV vectors and is typically measured as vector genomes per milliliter (vg/mL) using qPCR or ddPCR. Accurate titer determination is critical for dose selection in both preclinical and clinical settings.

Integrity
Integrity refers to the structural and genomic completeness of AAV particles. This includes intact capsids and full-length genomes. Compromised integrity can reduce transgene expression and affect product stability.

Infectivity (Potency)
Infectivity describes the ability of AAV particles to successfully transduce target cells and express the transgene. Because not all particles are functional, infectivity assays provide an important complement to genome-based titer measurements.

Analytical Challenges in AAV Quality Control

Despite significant progress in analytical technologies, several challenges remain in accurately characterizing AAV CQAs.

Accuracy of titer measurement
AAV preparations often contain a mixture of full, empty, and partially packaged capsids. Genome-based assays quantify nucleic acid content but do not distinguish functional particles, leading to potential discrepancies between measured titer and biological activity.

Sensitivity of purity analysis
Impurities such as host cell proteins and residual DNA may be present at very low levels but still impact safety. Detecting and quantifying these trace contaminants requires highly sensitive and validated analytical methods.

Assessment of particle integrity
Evaluating capsid integrity and genome completeness is technically challenging. Methods such as electron microscopy, analytical ultracentrifugation, and sequencing-based approaches provide insight, but each has limitations in throughput, resolution, or quantification.

Complexity of infectivity assays
Infectivity or potency assays often require biologically relevant cell systems, which can introduce variability. Differences in cell type, receptor expression, and assay conditions can significantly affect results, making standardization difficult.

Strategies to Address Analytical Challenges

To overcome these challenges, the field is moving toward more integrated and standardized analytical approaches.

Methodological innovation
Advances in technologies such as digital PCR, mass photometry, and next-generation sequencing are improving the accuracy and resolution of AAV characterization.

Standardization and harmonization
Developing standardized assay protocols and reference materials can improve comparability across laboratories and manufacturing sites.

Orthogonal, multi-attribute analysis
No single assay is sufficient to define AAV quality. Combining multiple complementary methods enables a more comprehensive assessment of CQAs.

Cross-sector collaboration
Collaboration between academia, industry, and regulatory agencies is essential to establish best practices and address unresolved analytical gaps.

Key Considerations for AAV Quality Control

Effective AAV quality control strategies typically include:

• Integration of genome, capsid, and functional assays

• Use of validated and reproducible analytical methods

• Alignment of CQAs with clinical relevance and mechanism of action

• Continuous refinement of assays during process development

These principles help ensure that analytical data accurately reflect product performance.

Conclusion

The identification and control of critical quality attributes are central to the successful development of AAV-based therapeutics. While analytical challenges remain—particularly in linking physical measurements to biological activity—ongoing innovation is steadily improving the precision and reliability of AAV quality control.

By adopting multi-dimensional analytical strategies and fostering collaboration across the field, researchers and manufacturers can better ensure that AAV products meet the highest standards of safety, efficacy, and consistency. This will ultimately support the broader goal of delivering reliable and effective gene therapies to patients.